HomeMarketInvesting in Teva Pharmaceutical Industries Limited (TEVA) Stock: Methodology

Investing in Teva Pharmaceutical Industries Limited (TEVA) Stock: Methodology

JP Morgan lowered the price target for the Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock from “a Neutral” to “an Underweight”. The rating was released on November 14, 2022, according to finviz. The research report from Jefferies has resumed the stock to Buy, with a price target set at $10. The stock was upgraded by BofA Securities, who disclosed in a research note on August 05, 2022, from Neutral to Buy and set the price objective to $13. In their research brief published June 14, 2022, UBS analysts resumed the Teva Pharmaceutical Industries Limited stock to Neutral with a price target of $10.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Teva Pharmaceutical Industries Limited (NYSE:TEVA) raised 1.26% to close Monday’s market session at $8.83, higher as compared to yesterday’s close. The stock price fluctuated between $8.515 and $8.85 throughout the trading session with the volume trading being 7015533 shares, which represented a significant variation when compared to the three months average volume of 9.48 million shares. The firm’s stock price fluctuated -5.46% within the last five trades and 4.62% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 4.50% in the last 6 months and -12.23% was subtracted to its value over the previous 3 months. TEVA stock is trading at a margin of -0.76%, 3.17% and 2.28% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


As of the close of trading, TEVA deals in the Healthcare domain. The stock is trading -22.13 percent below its 52-week high and 30.25 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -7.8. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Teva Pharmaceutical Industries Limited’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -7.70 percent and the profit margin is -8.50 percent, and the company has reported a gross margin of 49.30 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $9.92 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 3.53. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 0.65 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 1.12, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.88 percent of Teva Pharmaceutical Industries Limited shares are owned by insiders, and 49.70 percent are held by financial institutions. Kalif Eliyahu Sharon, the EVP, Chief Financial Officer at Teva Pharmaceutical Industries Limited (TEVA) has sold 55,500 shares of firm on Aug 22 at a price of $10.07 against the total amount of $0.56 million. In another inside trade, Stark David Matthew, Exec. VP Chief Legal Officer of Teva Pharmaceutical Industries Limited (NYSE:TEVA) sold 58,163 shares of the firm on Jul 28 for a total worth of $0.53 million at a price of $9.04. An inside trade which took place on May 17, Executive VP, Global R&D of Teva Pharmaceutical Industries Limited Fridriksdottir Hafrun sold 130,000 shares of firm against total price of $1.07 million at the cost of $8.22 per share.



Please enter your comment!
Please enter your name here

Recent Post

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.